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ABSTRACT
Background: Phosphodiesterase 4 selective inhibitor may prevent airway inflammation and remodeling.
Objective: The aim of this study was to investigate the effects of KF19514, a phosphodiesterase 4 and 1 dual
inhibitor, on chronic airway inflammation and remodeling following chronic exposure to aerosolized antigen in
mice.
Methods: Ovalbumin (OVA) was administered intraperitoneally to BALBc mice on days 0 and 14, and the
mice were then exposed to aerosolized OVA daily for 4 weeks. Twenty-four hours following the final inhalation,
bronchial responsiveness to acetylcholine was measured, and histologic examination and hydroxyproline con-
tent of the lung were evaluated.
Results: Bronchial responsiveness to acetylcholine, number of inflammatory cells and eosinophils in the lam-
ina propria, thickness of epithelial and subepithelial collagen layers, and hydroxyproline content of the lung in-
creased following chronic exposure to OVA for 7 weeks. KF19514 significantly prevented all of these changes.
Conclusions: Phosphodiesterase 4 and 1 inhibitors such as KF19514 may help prevent bronchial hyperre-
sponsiveness and chronic asthma-induced airway remodeling.
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INTRODUCTION
A characteristic feature of airway pathology in pa-
tients with chronic asthma, in addition to chronic
eosinophilic airway inflammation, is an increase in
the extracellular matrix within the lamina propria
layer beneath the true epithelial basement mem-
brane, namely subepithelial fibrosis.1 Remodeling of
the airway structure is thought to be due to an in-
creased deposition of collagen I, III, and V; fi-
bronectin; and tenascin in this area1-3 in association
with subepithelial myofibroblast proliferation,4 which
reflects the consequences of recurrent injury and ab-
errant repair processes in the airway wall. Subepithe-
lial fibrosis may partially contribute to the increase in
airway wall stiffness, poor airway reversibility, and
poor responsiveness to inhaled corticosteroids even
after prolonged therapy.5-7 The remodeling changes
correlate with the development of airway hyperreac-
tivity (AHR)8 and with persistent airflow limitations in
chronic asthma patients.9 Long-term titration of in-
haled glucocorticoid therapy to reduce AHR, which
substantially improves clinical outcome, is associated
with a significant reduction in subepithelial fibrosis.10
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Fig. 1 Experimental protocol
OA 50 μg
Al (OH) 3ޓ5.0 mg      i.p.
0.1 ml saline
OA 30 mg/ml, inhalation 
(20 min./day, every day)
Measurements and analysis
・Bronchial hyper responsiveness to  
ACh (250, 500, 1000, 2000 and 4000
μg/ml, 0.05 ml i.v.) 
・Histological examination
(H.E, Azan Mallory stain)
・Hydroxyproline content (rt. lung)
Day 0 Day 14 Day 21 Day 48 Day 49
4 wks
Saline
KF19514  0.1 mg/kg       i.p.
KF19514  1.0 mg/kg (once a day, every day)
Negative control: Saline i.p. and saline challenge 
Phosphodiesterase (PDE) isoenzymes control the
degradation of cyclic adenosine monophosphate and
thus have key roles in regulating compartmentalized
signaling responses to intracellular gradients of cyclic
AMP.11 The PDE4 family of enzymes, comprises four
PDE4 genes, which generate at least 16 different iso-
forms, exclusively hydrolyze cyclic AMP, and most of
this activity occurs within cells.12 KF19514, a novel
potent PDE4 and PDE1 dual inhibitor, is an effective
anti-inflammatory agent in animal models of acute al-
lergen challenge, inhibiting antigen-induced bron-
chospasm.13-15 Roflumilast, a novel potent PDE4-
selective inhibitor,16 inhibits airway inflammation and
remodeling,17 however, whether PDE4 and PDE1 in-
hibitors prevent airway inflammation and remodeling
in chronic asthma is unknown. We therefore exam-
ined the ability of KF19514 to inhibit airway inflam-
mation, remodeling, and AHR in mice following
chronic exposure to aerosolized antigen.
METHODS
ANIMALS
Specific pathogen-free female BALBc mice (6 to 8
weeks of age) were obtained from Ninnox Laboratory
Service (Ishikawa, Japan). After arrival at the Institute
of Animal Experiments at our university, the mice
were maintained in conventional animal housing fa-
cilities for 1 week before use and were allowed to
drink and eat ad libitum. The experiment was per-
formed according to the Principles of Laboratory Ani-
mal Care formulated by the Institute of Animal Ex-
periments at Kanazawa University.
EXPERIMENTAL PROCEDURE
Sensitization of mice with OVA was performed ac-
cording to the method by Temelkovski et al.18 with
minor modifications. A mixed suspension of 50 g
OVA and 5 mg aluminum hydroxide in 0.1 ml physi-
ologic saline was administered intraperitoneally to
mice once on Days 0 and 14. From Day 21, 30 min-
utes after intraperitoneal administration of 0.1 or 1.0
mgkg of KF19514 or physiologic saline, mice were
placed in a closed plastic inhalation chamber
(length × width × height = 24 cm × 21 cm × 17 cm)
and exposed to aerosol consisting of 3.0% wv OVA
suspended in physiologic saline for 20 minutes, every
day for 4 weeks. Aerosol with particle diameters be-
tween 1 and 10 μm, was generated and administered
at a flow of 0.3 mlmin using an ultrasonic nebulizer
(Model C-13, Omron, Tokyo, Japan) in the exposure
chamber. Control animals were treated in a similar
way except that the physiologic saline did not contain
OVA and aluminum hydroxide (Fig. 1).
MEASUREMENT OF AIRWAY RESPONSIVENE-
SS
We anesthetized the mice with 2.5 mg, i.p. sodium
pentobarbital 24 hours after the final inhalation of an-
tigen then placed them in a supine position. The tra-
chea was incised and cannulated with a 20-gauge ny-
lon needle (inner diameter; 0.80 mm, length; 32 mm),
and animals were artificially ventilated using a small-
animal respirator (Model 1680, Harvard Apparatus,
South Natick, MA, USA) adjusted to deliver a tidal
volume of 0.5 ml at a rate of 60 strokesminute. The
change in lung resistance to inflation, and the lateral
PDE4 & 1 Inhibitor on Airway Remodeling
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Fig. 2 Airway reactivity of unexposed and OVA-sensitized 
chronicaly exposed mice to saline alone or 0.1 mg/kg and 
1.0 mg/kg KF19514, as assessed by the change in Pao in re-
sponse to increasing concentrations of aerosolized 
acetylcholine. Circles indicate response in saline-exposed 
animals (naïve mice) (n＝8). Solid circles indicate response 
after administration of saline in OVA-sensitized mice (n＝
10). Solid squares indicate response after administration of 
0.1 mg/kg KF19514 in OVA-sensitized mice (n＝10). Solid 
triangles indicate response after administration of 1.0 mg/kg 
KF19514 in OVA-sensitized mice (n＝10). Each point indi-
cates mean SEM. Significant diferences compared with 
saline-treated OVA-sensitized mice are shown as ＊, p＜
0.05; ＊＊, p＜0.01.
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pressure in the tracheal tube (pressure at the airway
opening; Pao, cmH2O), was determined using the
modified method by Konzett and Rossler described
by Jones et al.19 using a pressure transducer (Model
TP-603T, Nihon Koden Kogyo, Tokyo, Japan). Since
the change in Pao following inhalation of leukotriene
C4 (LTC4) represents the average of the changes in
pulmonary resistance (RL) and reciprocal dynamic
lung compliance (1Cdyn),21 we used Pao as an over-
all index of bronchial response to the bronchoactive
agent. Airway reactivity to intravenous acetyl-
choline20 was measured 24 hours after the final inha-
lation of antigen. Spontaneous breathing was blocked
by injection of pancuronium bromide (0.1 mgkg)
into the jugular vein. Ten minutes after initiating arti-
ficial ventilation, when the Pao was stabilized, five
successive intravenous administrations of acetyl-
choline hydrochloride (250, 500, 1000, 2000, and 4000
gml, 0.05 mlanimal) were performed at 5-minute in-
tervals with constant monitoring of the bronchopul-
monary response. Pao was continuously recorded as
described above and expressed as a percentage of
the baseline value.
HISTOLOGIC STUDY
After the measurement of acetylcholine-induced
bronchoconstriction as described above, the mice
were killed with an overdose of pentobarbital. The
left lung was removed and inflated with 1 ml of 10%
neutral buffered formalin and sectioned. After fixation
overnight in formalin, the tissue was embedded in
paraffin. The sections were cut in the longitudinal
plane of the bronchus and lung, stained in one batch
with either haematoxylin and eosin (H&E) for meas-
uring the thickness of the epithelial cell layer and the
inflammatory cell (lymphocyte, neutrophil, eosino-
phil) numbers, or Azan-Mallory solution for determin-
ing subepithelial collagen deposition. The sections
were then coded for morphometry. Histologic analy-
sis was performed by an observer with no knowledge
of the experimental procedures.
After general observation, the thickness of the epi-
thelial cell layer was measured on H&E -stained sec-
tions, randomly selected from each animal. The
analyses were made along either side of the longitudi-
nally - cut airway wall. The measurements were made
only in bronchi greater than 150 μm in diameter and
at locations where the epithelium appeared intact and
well-orientated to minimize the influence of tangential
sectioning, using an oil immersion objective (×1000)
and an eyepiece graticule as previously descri-
bed.18,21 The data were recorded to the nearest half
division on the reticle (0.5 μm). After the measure-
ments were completed in one field, the microscopic
stage was advanced a linear distance of two micro-
scopic fields and measurements were repeated. For
each animal, the average thickness of the epithelial
cell layer was determined for 20 fields and at least 75
points (mean 81 ± 3) at 20 μm intervals. The areas
covered 1.6 mm of the basement membrane length.
The mean thickness of the epithelial cell layer was
then calculated.
The density of eosinophils in the lamina propria
was also measured in H&E-stained sections. The lam-
ina propria was defined as the zone between the epi-
thelial basement membrane and the luminal border
of the tracheal cartilage plates and smooth muscle
layer in the bronchi. Eosinophils were readily identi-
fied based on specifically staining granules in cyto-
plasm. When eosinophils were counted in a field, the
length of the epithelial cell layer was measured. For
each animal, at least 15 fields, which covered 2.3 mm
of epithelial basement membrane length were ana-
lyzed, and the number of cells per 1000 μm2 base-
ment membrane was determined. Measurement of
the epithelial thickness was performed in the same
field used for cell counting, with at least 23 (mean
28 ± 2) measurements for each animal.
The thickness of the subepithelial collagen deposi-
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Fig. 3 Photomicrographs showing inflammatory cels and eosinophils (arows) in the lamina propria and 
thickening of the epithelial and subepithelial colagen layers. Lung tissues were obtained from unexposed 
mice (a) OVA-sensitized chronicaly exposed mice treated with saline; (b) 0.1 mg/kg KF19514; (c) 1.0 
mg/kg KF-19514 and (d) (H&E stain). Original magnification, × 1000.
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tion areas was analyzed on Azan-Mallory-stained sec-
tions in the same way as described above for deter-
mining the thickness of the epithelium basement
membrane. On average, the positive zones beneath
the epithelium were measured in 20 fields and at 80
points on each section. The data were taken along 1.5
to 1.8 mm of the basement membrane from which
the mean thickness of the subepithelial collagen layer
was calculated for each mouse.
MEASUREMENT OF AMOUNT OF HYDROXY-
PROLINE IN THE LUNG
The right lung of each mouse was removed and
stored at −80℃ for the measurement of hydroxy-
proline immediately after the measurement of
acetylcholine-induced bronchoconstriction. The ex-
tent of pulmonary fibrosis was evaluated by estimat-
ing total lung collagen deposition as reflected by hy-
droxyproline content measured in control and
antigen-exposed mice. Measurement of the amount
of hydroxyproline was performed according to the
method described by Huszar et al.23 with minor modi-
fications.
CHEMICALS
The following chemicals were used: OVA (Sigma
Chemicals, St. Louis, MO, USA), sodium pentobarbi-
tal (Abbott Laboratories, North Chicago, IL, USA),
aluminum hydroxide (Wako Pure Chemical Indus-
tries, Osaka, Japan), pancuronium bromide (Tocris
Cookson, Bristol, UK), acetylcholine hydrochloride
(Wako Pure Chemical Industries, Osaka, Japan), and
KF19514 (5-phenyl-3-(3-pyridil) methyl-3H-imidazo
[4,5-c][1,8]naphthyridin-4 (5H)-one-(Chemical Syn-
thesis Division of Pharmaceutical Research Laborato-
ries, Kyowa Hakko Kogyo, Shizuoka, Japan).
STATISTICAL ANALYSIS
The mean and standard error (SEM) were calculated
for all parameters in this study. Statistical analyses
were performed by analysis of variance (ANOVA) for
four groups and unpaired t-test for two groups. Dose-
response curves for acetylcholine-induced bron-
choconstriction were also analyzed by two-factor re-
peated measures ANOVA. A P value of 0.05 or less
was considered to indicate a statistically significant
difference.
RESULTS
ACETYLCHOLINE-INDUCED BRONCHOCONST-
RICTION
We first evaluated the bronchial responsiveness to
acetylcholine. Figure 2 shows dose-response curves
for the effect of intraperitoneal administration of
PDE4 & 1 Inhibitor on Airway Remodeling
Allergology International Vol 58, No2, 2009 www.jsaweb.jp 271
Fig. 4 Inflammatory cels in the lamina propria of the tra-
chea of OVA-sensitized, chronicaly exposed mice treated 
with saline (n＝10) compared to unexposed control mice (n
＝8) or to mice treated with 0.1 mg/kg KF19514 (n＝10) or 
1.0 mg/kg KF19514 (n＝ 10). Each bar indicates mean 
SEM. Significant diferences compared with saline-treated 
OVA-sensitized mice are shown as ＊＊, p＜0.01. Significant 
diferences compared with 0.1 mg/kg KF19514-treated OVA-
sensitized mice are shown as ##, p＜0.01.
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Fig. 5 Eosinophils in the lamina propria of the trachea of 
OVA-sensitized, chronicaly exposed mice treated with sa-
line (n＝10) compared to unexposed control mice (n＝8) or 
to mice treated with 0.1 mg/kg KF19514 (n＝ 10) or 1.0 
mg/kg KF19514 (n＝ 10). Each bar indicates mean SEM. 
Significant diferences compared with saline-treated in OVA-
sensitized mice are shown as ＊＊, p＜0.01.
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KF19514 on acetylcholine-induced bronchoconstric-
tion. Chronic exposure to OVA induced significant
bronchial-hyperresponsiveness in OVA-sensitized
mice (n = 10), as compared with saline-exposed ani-
mals (naïve mice, n = 8; p < 0.01). The dose-response
curves of the acetylcholine-induced increase in Pao
was significantly and dose-dependently inhibited by
KF19514 (Fig. 2).
ANALYSIS OF MORPHOLOGIC CHANGES AF-
TER CHRONIC ANTIGEN EXPOSURE
Thereafter we evaluated the morphologic changes af-
ter chronic OVA exposure in mice. Consistent with
the morphologic analyses of H&E-stained tissue sam-
ples (Fig. 3), chronic OVA exposure resulted in sig-
nificant increases in the amount of peribronchial and
perivascular infiltration of inflammatory cells, pre-
dominantly consisting of eosinophils infiltrating the
lamina propria in the airway of OVA-sensitized mice
(n = 10), as compared with saline-exposed mice (n =
10). Intraperitoneal administration of KF19514 inhib-
ited an increase in inflammatory cells, consisting of
eosinophils, in the lamina propria in the airway of
mice after chronic OVA exposure in a dose-
dependent manner (Fig. 4, 5). Moreover, chronic
OVA exposure induced significant increases in the
thickness of the epithelial and subepithelial collagen
layers in the airway of OVA-sensitized mice, com-
pared with saline-exposed mice. Intraperitoneal ad-
ministration of KF19514 decreased the thickness in
epithelial and subepithelial collagen layers after
chronic OVA exposure in a dose-dependent manner
(Fig. 6, 7).
HYDROXYPROLINE OF THE LUNG
We evaluated the amount of hydroxyproline in the
lung. Chronic exposure to OVA resulted in a signifi-
cant increase in the hydroxyproline content of the
right total lung, compared with saline-exposed mice.
Intraperitoneal administration of KF19514 inhibited
the increase in hydroxyproline content after chronic
OVA exposure in a dose-dependent manner (Fig. 8).
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Fig. 6 Thickness of epithelium in the trachea of OVA-sen-
sitized, chronicaly exposed mice treated with saline (n＝
10) compared to unexposed control mice (n＝8) or to mice 
treated with 0.1 mg/kg KF19514 (n＝ 10) or 1.0 mg/kg 
KF19514 (n＝ 10). Each bar indicates mean SEM. Signifi-
cant diferences compared with saline-treated OVA-sensi-
tized mice are shown as ＊＊, p＜ 0.01. Significant 
diferences compared with 0.1 mg/kg KF19514-treatment in 
OVA-sensitized mice are shown as #, p＜0.05.
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Fig. 7 Thickness of subepithelial colagen layer of the tra-
chea of OVA-sensitized, chronicaly exposed mice treated 
with saline (n＝10) compared to unexposed control mice (n
＝8) or to mice treated with 0.1 mg/kg KF19514 (n＝10) or 
1.0 mg/kg KF19514 (n＝ 10). Each bar indicates mean 
SEM. Significant diferences compared with saline-treated 
OVA-sensitized mice are shown as ＊＊, p＜0.01. Significant 
diferences compared with 0.1 mg/kg KF19514-treated OVA-
sensitized mice are shown as ##, p＜0.01.
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DISCUSSION
We set out to determine whether selective PDE 4 and
1 dual inhibitor KF19514 might be useful for prevent-
ing bronchial hyperresponsiveness and airway re-
modeling in asthma. Airway remodeling is now con-
sidered to be an important feature of chronic asthma
and is postulated to promote the progression of the
disease to a chronic irreversible stage.24 The patho-
physiology of remodeling and its effects on airway
physiology remain to be fully established. Airway in-
flammation and remodeling in chronic asthma are
characterized by airway eosinophilia, hyperplasia of
goblet cells and smooth muscle, and subepithelial fi-
brosis. Chronic airway inflammation is an important
aspect of asthma pathogenesis.1 Eosinophil infiltra-
tion into the airway and airway hyperreactivity are
now thought to be regulated by Th2 cytokines and
chemokines.25 Interleukin-4 (IL-4) and IL-13 are es-
sential for immunoglobulin E production, while IL-5,
eotaxin, and RANTES, a member of the 8-kDa cy-
tokine family possesses chemotactic activity for
monocytes and CD4 T cells, are important for eosino-
phil recruitment. 26 Monocyte chemoattractant
protein-1 is involved in airway hyperreactivity via its
capability to degranulate mast cells.27
In this study, we used a mouse model of chronic
asthma established by inducing airway inflammation
and airway wall remodeling over a 4-week period and
promoted through continued antigen exposure.18 We
investigated the effect of PDE 4 and 1 dual inhibitor
KF19514 in this mouse model of antigen-induced
chronic airway inflammation and fibrosis. Chronic ex-
posure of OVA-sensitized mice to aerosolized OVA-
induced bronchial hyperresponsiveness and airway
eosinophilic inflammation and fibrosis. Intraperito-
neal administration of KF19514 inhibited the chronic
OVA exposure-induced bronchial hyperresponsive-
ness, airway inflammation, and fibrosis in a dose-
dependent manner.
Recently, at least 11 different cyclic nucleotide
PDE isozymes were identified based on functional
PDE4 & 1 Inhibitor on Airway Remodeling
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Fig. 8 Hydroxyproline content in OVA-sensitized, chroni-
caly exposed mice treated with saline (n＝10) compared to 
unexposed control mice (n＝ 8) or to mice treated with 0.1 
mg/kg KF19514 (n＝ 10) or 1.0 mg/kg KF19514 (n＝ 10). 
Each bar indicates mean SEM. Significant diferences com-
pared with saline-treated in OVA-sensitized mice are shown 
as ＊, p＜0.05; ＊＊, p＜0.01.
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characteristics, such as substrate specificity and sus-
ceptibility to selective inhibitors.28 KF19514 is a new
potent and highly-selective inhibitor of PDE4 and
PDE1 isoenzymes.29 The IC50 values of KF19514 for
PDE1, PDE2, PDE3, PDE4, and PDE5, derived from
canine tracheal smooth muscle, are 0.27, > 10, >10,
0.40, and >10 μmolL, respectively.13 Both oral and
intravenous administration of PDE4 inhibitors such
as rolipram and Ro-20-1724 have antiallergic effects30-
33 as well as bronchodilator effects.34,35 Howell and
coworkers30 reported that rolipram has pulmonary
antiallergic effects, including the inhibition of
antigen-induced full and leukotriene-dependent bron-
choconstriction and prevention of antigen-induced
airway hyperreactivity, with minimal relaxant effects
on airway smooth muscle. Teixeire et al.36 reported
that rolipram effectively inhibits allergic- and
mediator-induced eosinophil accumulation. On the
other hand, PDE1 inhibition by KF19514 does not
seem to contribute to the inhibition of inflammatory
cell accumulation, because vinpocetine, a selective
PDE1 inhibitor, does not inhibit eosinophil accumula-
tion.37,38 These findings suggest that the inhibitory ef-
fects of KF19514 on bronchial hyperresponsiveness,
airway inflammation, that develop following chronic
antigen exposure result from KF19514 antagonism of
PDE4 and not PDE1.
Selective PDE4 inhibitors, which act against the
catalytically active site, inhibit the function of a vari-
ety of inflammatory and immunomodulatory cells.39
These compounds decrease the production of numer-
ous relevant inflammatory mediators, including hista-
mine and leukotrienes,40 proinflammatory cytokines
such as tumor necrosis factor-α and IL-1,41 and T-
lymphocyte-derived cytokines such as IL-4 and IL-5.42
Corbel et al. reported that selective PDE4 inhibitors
such as RP 73―401 might modulate the expression of
airway remodeling-associated mediators such as ma-
trix metalloproteinase-9 and transforming growth
factor-α and that this effect may be at least partially
mediated by the balance between tumor necrosis
factor- and IL-10.43
Here, we did not evaluate inflammatory mediators
such as histamine and leukotrienes, proinflammatory
cytokines such as tumor necrosis factor-α, IL-1, IL-4,
and IL-5, and airway remodeling-associated mediators
such as matrix metalloproteinase-9 and transforming
growth factor-α. Airway inflammation and remodeling
are thought to have a profound effect on airway re-
sponse. Inflammatory cells give rise to airway respon-
siveness by releasing chemical mediators, cytokines,
and chemokines in the local microenvironment, re-
sulting in physiologic changes observed in asthma
and sustained airway inflammation. Increased airway
wall thickness caused by the remodeling process
strengthens the effect of smooth-muscle contractions
as explained by Poiseuille’s law of laminar flow, and
contributes to airway hyperresponsiveness.44 Roflu-
milast, a novel potent PDE4-selective inhibitor, is a
potent inhibitor of airway inflammation and remodel-
ing.17
PDE1 was implicated in human vascular smooth
muscle proliferation45,46 and it is tempting to specu-
late that one or more PDE1 isoenzymes could serve
the same function in airway myocytes. In humans,
PDE1s are encoded by three genes (PDE1A, PDE1B
and PDE1C), Rybalkin et al.45 found that PDE1C was
markedly induced in proliferating, but not in quies-
cent, smooth muscle cells that are derived from hu-
man aorta. Furthermore, as in human airway myo-
cytes, this enzyme was the predominant PDE in
these cells. The induction of PDE1C lowers cAMP in
vascular myocytes and therefore relieves an endoge-
nous ‘break’, which allows mitogenesis to proceed
unhindered. Given that airway remodeling is a char-
acteristic of COPD and other airway inflammatory
diseases, such as chronic severe asthma, dual-
specificity inhibitors of PDE1C and PDE4 might se-
lectively target proliferating airway smooth muscle
cells and, by doing so, retard the remodeling process
(PDE1C-mediated) and arrest inflammation (by way
of PDE4 inhibition).47
KF19514, a PDE4 and PDE1 dual inhibitor, showed
Kita T et al.
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an antiallergic effect, probably via its inhibitory activ-
ity of antigen-induced mediator release, in addition to
a functional bronchoprotective effect via PDE4 inhibi-
tion and inhibition through the remodeling of airway
smooth muscle via PDE1 and PDE4 inhibition. This
dual inhibitor of PDE4 and PDE1 is more clinically
usefull in preventing airway remodeling in asthma
than the inhibitor of only PDE4. In conclusion, our re-
sults indicate that selective PDE 4 and 1 dual inhibi-
tor KF19514 might be useful for preventing bronchial
hyperresponsiveness and airway remodeling in
asthma.
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